Navigation Links
Protein Linked With Poor Prognosis in Early-Stage Breast Cancer
Date:1/30/2008

But expression of Ki-67 didn't predict who'd benefit from additional chemo

WEDNESDAY, Jan. 30 (HealthDay News) -- High levels of a protein called Ki-67 are associated with poor prognosis in women with early-stage breast cancer, but this protein may not be useful in identifying patients who would benefit from additional chemotherapy, an Italian study suggests.

Some studies have suggested that breast tumors with a high percentage of tumors cells expressing Ki-67 are more responsive to chemotherapy. This study looked at whether Ki-67 levels predicted responsiveness to chemotherapy in women who'd had surgery for breast cancer.

Researchers at the University of Milan in Italy assessed Ki-67 expression in tumor samples from women in two randomized clinical trials comparing the use of endocrine therapy alone to endocrine therapy after chemotherapy.

They found that Ki-67 expression didn't predict which women would benefit from chemotherapy prior to endocrine therapy, but they did find that having a high percentage of tumor cells expressing Ki-67 was associated with poorer disease-free survival.

"In this study, Ki-67 [expression] was a prognostic factor, not a predictive factor," the study authors wrote.

The findings were published in the Jan. 29 issue of the Journal of the National Cancer Institute.

These results support the position of the American Society of Clinical Oncology Tumor Markers Expert Panel that Ki-67 shouldn't be used to make decisions about chemotherapy, Matthew Ellis, of Washington University in St. Louis, wrote in an accompanying editorial.

"Biomarker studies with negative results can be just as important to publish as those with positive results, because clinging to a long-favored but incorrect hypothesis in the face of negative evidence impedes scientific and clinical progress," Ellis wrote.

More information

Breastcancer.org has mo
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
4. Emory researchers identify signaling protein for multiple myeloma
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Lowering Blood Protein Wont Help Kidney Patients
7. Blood protein detects lung cancer, even at earliest stage
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Heat shock proteins are co-opted for cancer
10. How adhesive protein causes malaria
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Protein Linked With Poor Prognosis in Early-Stage Breast Cancer
Protein Linked With Poor Prognosis in Early-Stage Breast Cancer
Other Medicine News:Health News:Penn talks at ASCB touch on cancer, neurodegenerative diseases, and MD 2Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 2Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 3Health News:Leading Epilepsy Groups Unveil New Survey Results Challenging Patients to Take Charge of Their Health 4Health News:New Study Links Animal Agriculture to More Than 20% of MRSA Infections in the Netherlands 2Health News:Neuro Kinetics Appoints Dr. Terri Ives Clinical Director, Audiology 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Aerosol launches immune response in lungs to wipe out lethal infections 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Emission capture study funded for paper industry 10353 1Emission capture study funded for paper industry 10353 2Emission capture study funded for paper industry 10353 3Fear of being laughed at crosses cultural boundaries 10348 1Fear of being laughed at crosses cultural boundaries 10348 2Fear of being laughed at crosses cultural boundaries 10348 3Fear of being laughed at crosses cultural boundaries 10348 4Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 1Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 2